The impact of choline supplementation on oxidative stress and clinical outcomes among patients with non-alcoholic fatty liver disease: a randomized controlled study.
Sylvia S Sedhom, Lamia M El Wakeel, Eman M F Barakat, Hend I Shousha, Mostafa A Shamkh, Salwa H Salama, Doaa Z Zaky, Amal A El Kholy
{"title":"The impact of choline supplementation on oxidative stress and clinical outcomes among patients with non-alcoholic fatty liver disease: a randomized controlled study.","authors":"Sylvia S Sedhom, Lamia M El Wakeel, Eman M F Barakat, Hend I Shousha, Mostafa A Shamkh, Salwa H Salama, Doaa Z Zaky, Amal A El Kholy","doi":"10.1177/20406223251358659","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Non-alcoholic fatty liver disease (NAFLD) is a prevalent condition characterized by the accumulation of fat in the liver. Nutrition, particularly micronutrients, plays a crucial role in the development and progression of NAFLD.</p><p><strong>Objectives: </strong>This study aimed to assess the impact of choline supplementation on oxidative stress, inflammation, and clinical outcomes in patients with NAFLD.</p><p><strong>Design: </strong>A randomized, controlled, single-blinded study.</p><p><strong>Methods: </strong>Eligible NAFLD patients were randomized to; <i>choline group</i> (<i>n</i> = 39), received conventional management plus phosphatidylcholine (PC) 2400 mg/day for 12 weeks, or c<i>ontrol group</i> (<i>n</i> = 40), received conventional management for 12 weeks, and 10 healthy volunteers were included. Anthropometric, clinical, and laboratory evaluations were performed at baseline and after treatment.</p><p><strong>Results: </strong>After 12 weeks, choline group showed significant differences versus controls by improvement in controlled attenuation parameter (304 vs 332 dB/m, <i>p</i> < 0.001) and fibrosis score (5.3 vs 6.8 kPa, <i>p</i> < 0.001), reduction in thiobarbituric acid reactive substances levels (1.9 vs 3.8 nmol/mL, <i>p</i> < 0.001), a decline in leptin levels (1.3 vs 2.1 ng/mL, <i>p</i> < 0.001) and liver enzyme (alanine aminotransferase and aspartate aminotransferase), <i>p</i> < 0.001 and 0.004 respectively). Also, the lipid profile improved by a significant decline in triglyceride levels in choline versus controls 133 versus 158, <i>p</i> = 0.048.</p><p><strong>Conclusion: </strong>Choline supplementation in NAFLD patients demonstrated a favorable impact on hepatic steatosis, oxidative stress, inflammatory markers, liver enzyme levels, and lipid profile. These findings suggest that choline may be a promising therapeutic option for NAFLD management. Further large-scale, long-term studies are warranted to investigate the clinical benefits of choline supplementation in NAFLD patients.</p><p><strong>Trial registration: </strong>The study was registered at clinicaltrials.gov and given the ID number: NCT05200156.</p>","PeriodicalId":22960,"journal":{"name":"Therapeutic Advances in Chronic Disease","volume":"16 ","pages":"20406223251358659"},"PeriodicalIF":2.8000,"publicationDate":"2025-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12361734/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Chronic Disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/20406223251358659","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Non-alcoholic fatty liver disease (NAFLD) is a prevalent condition characterized by the accumulation of fat in the liver. Nutrition, particularly micronutrients, plays a crucial role in the development and progression of NAFLD.
Objectives: This study aimed to assess the impact of choline supplementation on oxidative stress, inflammation, and clinical outcomes in patients with NAFLD.
Design: A randomized, controlled, single-blinded study.
Methods: Eligible NAFLD patients were randomized to; choline group (n = 39), received conventional management plus phosphatidylcholine (PC) 2400 mg/day for 12 weeks, or control group (n = 40), received conventional management for 12 weeks, and 10 healthy volunteers were included. Anthropometric, clinical, and laboratory evaluations were performed at baseline and after treatment.
Results: After 12 weeks, choline group showed significant differences versus controls by improvement in controlled attenuation parameter (304 vs 332 dB/m, p < 0.001) and fibrosis score (5.3 vs 6.8 kPa, p < 0.001), reduction in thiobarbituric acid reactive substances levels (1.9 vs 3.8 nmol/mL, p < 0.001), a decline in leptin levels (1.3 vs 2.1 ng/mL, p < 0.001) and liver enzyme (alanine aminotransferase and aspartate aminotransferase), p < 0.001 and 0.004 respectively). Also, the lipid profile improved by a significant decline in triglyceride levels in choline versus controls 133 versus 158, p = 0.048.
Conclusion: Choline supplementation in NAFLD patients demonstrated a favorable impact on hepatic steatosis, oxidative stress, inflammatory markers, liver enzyme levels, and lipid profile. These findings suggest that choline may be a promising therapeutic option for NAFLD management. Further large-scale, long-term studies are warranted to investigate the clinical benefits of choline supplementation in NAFLD patients.
Trial registration: The study was registered at clinicaltrials.gov and given the ID number: NCT05200156.
背景：非酒精性脂肪性肝病（NAFLD）是一种以肝脏脂肪堆积为特征的常见病。营养，特别是微量营养素，在NAFLD的发生和发展中起着至关重要的作用。目的：本研究旨在评估胆碱补充对NAFLD患者氧化应激、炎症和临床结果的影响。设计：随机、对照、单盲研究。方法：符合条件的NAFLD患者随机分为；胆碱组（n = 39），采用常规管理+磷脂酰胆碱（PC） 2400 mg/天，连续12周；对照组（n = 40），采用常规管理，连续12周，其中健康志愿者10名。在基线和治疗后进行人体测量学、临床和实验室评估。结果：12周后，胆碱组与对照组相比，控制衰减参数（304 vs 332 dB/m, p p p p p p = 0.048）有显著性差异。结论：在NAFLD患者中补充胆碱对肝脂肪变性、氧化应激、炎症标志物、肝酶水平和脂质谱有有利影响。这些发现表明胆碱可能是NAFLD治疗的一种有希望的治疗选择。需要进一步的大规模长期研究来调查胆碱补充对NAFLD患者的临床益处。试验注册：该研究在clinicaltrials.gov上注册，ID号：NCT05200156。
期刊介绍：
Therapeutic Advances in Chronic Disease publishes the highest quality peer-reviewed research, reviews and scholarly comment in the drug treatment of all chronic diseases. The journal has a strong clinical and pharmacological focus and is aimed at clinicians and researchers involved in the medical treatment of chronic disease, providing a forum in print and online for publishing the highest quality articles in this area.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
